logo
RFK's MAHA report targets food, drug, tech industries: Key takeaways

RFK's MAHA report targets food, drug, tech industries: Key takeaways

The Hill22-05-2025

The Trump administration issued its long-awaited Make America Healthy Again (MAHA) report on Thursday, hammering various industries while deviating from mainstream science on key issues including farming practices, vaccinations and psychiatric medications.
President Trump appointed Health Secretary Robert Kennedy Jr. to lead the MAHA Commission, which issued its first report on children's health Thursday. It pointed to four key factors which it says are hurting U.S. children: ultra-processed foods, environmental chemicals, digital behavior and 'overmedicalization.'
The report identifies pesticides and other chemicals as potentially having harmful health impacts, but stops short of recommending actions to limit them – disappointing some advocates.
When it came to childhood mental and physical health, the report concludes that large corporations are distorting the U.S. health system for the sake of profits.
Here's what you should know:
'There is a growing concern about the link between environmental health risks, particularly cumulative risks, and chronic disease,' the report states.
'Furthermore, in the past nearly 30 years, the chemicals children are exposed to have grown – and no country fully understands how the cumulative impact of this growth impacts health,' it continues.
However, rather than calling for specific actions against these health threats, the report says more studies are needed, including from the National Institutes of Health, to fully understand the impacts of things like microplastics and pesticides.
In particular, it mentions glyphosate, the chemical in Roundup Weedkiller which has been the subject of thousands of lawsuits, many of which allege that it causes cancer, though the company has denied this.
The report also mentions Atrazine, a commonly used pesticide that has been found to disrupt the endocrine system and has been banned in the European Union
Also on the list to study more are PFAS, toxic substances used in nonstick and waterproof products that can last in the environment for hundreds of years, as well as phthalates, which are used to make plastics flexible and have been found to disrupt the endocrine system.
The Wall Street Journal reported that the White House altered the report to remove references to the company Monsanto, information about PFAS lobbying and conflicts of interest in chemical regulation.
Environmental Protection Agency Administrator Lee Zeldin told reporters that the Trump administration would not be pursuing a 'European, mandate-driven regulatory system that stifles growth.'
Lori Ann Burd, environmental health program director at the Center for Biological Diversity, told The Hill that identifying a problem but not pursuing actions was not good enough.
'It's really disappointing that, after all the promises that the commission was going to stand up to powerful corporate interests and really get to the bottom of what is making Americans so sick, it caved to these powerful corporate interests,' Burd said.
'They have joined every administration before them in cowering in fear when faced with the power of Big Ag,' she added.
Kennedy has been vocal in his belief that many medications like vaccines and psychiatric drugs are overused in the U.S. and, in aggregate, causing some of the health problems plaguing America's children.
These beliefs were reflected in the commission's findings.
The report noted the use of stimulant drugs, antidepressants, antipsychotics and asthma medications have all increased among children within the past 30 or so years. It further cast speculation on childhood vaccination schedules, noting that the number of vaccines implemented in the U.S. exceeds that of many European vaccine schedules.
'These time trends significantly outpace more moderate increases seen in other developed countries. Psychotropics for ADHD or one example, prescribed 2.5 times more in US than in British children, and 19 times more than in Japanese youth,' the report stated.
Kennedy has claimed that childhood psychiatric drugs are 'insufficiently scrutinized' and addictive. Childhood psychiatrists blasted Kennedy's rhetoric as unhelpful to children with mental illnesses.
'There is some concern, even more so in the field, that many children with depression and mental health disorders do not get access to the mental health services that they need, and that includes the comprehensive treatment that we would recommend, which is beyond just SSRIs, but also therapy and other supports,' Lisa Fortuna, a child psychiatrist and chair of the American Psychiatric Association's Council on Children, Adolescents and Their Families, previously told The Hill.
While stopping short of blaming vaccines for directly contributing to chronic illnesses and acknowledging that immunizations 'benefit children by protecting them from infectious diseases,' the report claimed there has been 'limited scientific inquiry into the links between vaccines and chronic disease.'
To improve the understanding of vaccines and any links to chronic disease, the report supported 'more rigorous clinical trial designs' that include placebos, larger sample sizes and longer follow-up periods.
Kennedy was perhaps the country's most prominent vaccine skeptic prior to becoming HHS Secretary. He has continually refused to acknowledge data disproving any links between vaccinations and autism, even when confronted during his confirmation hearing by Sen. Bill Cassidy (R-La.), himself a physician.
Under Kennedy and Food and Drug Commissioner Marty Makary, HHS has moved forward with plans to enforce a new requirement for placebo testing on all new vaccines, though how this rule will be implemented remains unclear. Placebo-controlled testing is already a standard part of the vaccine approval process and Kennedy told the Senate Appropriations Committee this week that he did not think it was ethical to retest all vaccines against a placebo.
The report blamed the 'overmedicalization of American children' on 'corporate capture.' It claimed the outsized influence of large corporations on public institutions had distorted 'scientific literature, regulatory processes, clinical practices and public discourse.'
'The corporate capture of media, primarily through lavish advertising campaigns that are uniquely targeted to American consumers (no other developed country allows direct advertising of drugs to consumers, other than New Zealand where such advertising is heavily regulated and federally controlled) confers a notable level of reliance on the industry by those that benefit financially,' the report read.
'While in the U.S. the pharmaceutical industry has the First Amendment right to have these advertisements, studies suggest that they have a strong influence on those who view them, potentially increasing inappropriate prescription.'
Again, there was not a recommendation to take action against pharmaceutical advertising, though the commission suggested the constant exposure to pharmaceutical advertisements was responsible for 'potentially increasing inappropriate prescriptions.'
The report blamed 'a sedentary, technology-driven lifestyle' that's developed over the past 40 years for increasing 'chronic physical and mental health diseases,' with childhood behaviors differing vastly from prior generations.
Citing data from the American Heart Association, the Centers for Disease Control and Prevention and numerous studies published within the last 15 years, the report noted how larger shares of children don't meet healthy standards of fitness and fewer children take part in daily physical activities.
These conclusions align with what has been observed globally, with a 2019 study finding that 81 percent of adolescents aged between 11 and 17 years of age were 'insufficiently physically active.'
'Parallel to the decline in physical activity, American youth face a deepening psychosocial crisis. This is marked by rising mental health disorders, significant sleep deficits, chronic stress, and pervasive loneliness, all exacerbated by the widespread influence of technology,' stated the report. 'The crisis persists despite rising therapy rates, with some suggesting it may exacerbate the issue.'
Social media use was also cited in the report as having a negative impact on childrens' mental health, echoing initiatives from the Biden administration. Then-Surgeon General Vivek Murthy issued a health advisory in 2023 warning that increasing evidence suggests social media use was damaging youth mental health.
At the same time, screen usage has also been potentially linked to a reduction in some risky behaviors, like substance use and motor vehicle accidents, though whether there is a direct cause is unclear.
As with 'overmedicalization,' the report took issue with the role that large corporations have in children's use of social media as well as public health messaging.
'Technology corporations suggest a reach over childhood health that stretches well beyond the direct harms of screen exposure, actively shaping the contours of scientific discourse and the public-health policies that follow,' it stated, noting how federal agencies coordinated with social media platforms during the COVID-19 pandemic.
'These informal, largely invisible coordination between agencies and platforms — coupled with undisclosed ranking algorithms — compresses the range of permissible debate on childhood-health questions and can bury legitimate scientific concerns while impacting parental supervision.'
Nathaniel Weixel contributed

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion
BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion

Yahoo

time25 minutes ago

  • Yahoo

BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion

BioNTech will acquire all shares of CureVac after the two sides reached an agreement in a deal valued around $1.25 billion. Each share of CureVac, a clinical-stage biotech company, will be exchanged for about $5.46 in BioNTech American depositary shares. Upon the deal's closing, CureVac shareholders are expected to own between 4% and 6% of the German developer of RNA vaccines and immunotherapies. ICE Raids Have Sent Latino Shoppers Into Hiding and Big Brands Are Hurting The Secret to Retaining the Best Employees: Ask Them These Four Questions Here's How Much Money the U.S. Is Earning From Tariffs, in Charts How Home Depot Became Ground Zero in Trump's Deportation Push Supply Chains Become New Battleground in the Global Trade War BioNTech Chief Executive Ugur Sahin said the plan is to bring complementary capabilities between the two companies together to develop transformative cancer treatments. CureVac's operating subsidiary will become a wholly owned subsidiary of BioNTech following the close of the transaction. As part of this plan, BioNTech will integrate CureVac's research and manufacturing site in Tübingen, Germany. The deal was unanimously approved by both companies' management and supervisory boards. It is expected to close in 2025. Shares of CureVac surged 29% to $5.25 in premarket trading. Write to Denny Jacob at Pulls Outlook as Sales Fall Bojangles Is Exploring a Sale While the Fried-Chicken Market Is Hot Why Bosses Should Give Feedback in the Morning The Audacious Reboot of America's Nuclear Energy Program Muted May Inflation Defies Tariff Fears Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge
Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge

Yahoo

time25 minutes ago

  • Yahoo

Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge

Most of UnitedHealth Group's issues should be temporary. The two biggest threats to the healthcare giant are iffy. The price is right to buy UnitedHealth Group stock after its steep decline. 10 stocks we like better than UnitedHealth Group › UnitedHealth Group (NYSE: UNH) might want to change its stock ticker from "UNH" to "UGH." The latter better captures the feelings of the healthcare giant's shareholders in recent months. A string of problems has caused UnitedHealth Group's share price to plunge roughly 50% from the peak set in the fourth quarter of 2024. Some analysts have downgraded the stock, with HSBC recommending that investors reduce their holdings and slashing its price target. I have a different opinion, though. I think it's time to buy UnitedHealth Group stock. Here are three reasons why. I don't think investors should ignore UnitedHealth Group's issues. However, the challenges should be viewed with a long-term perspective. I suspect most of the problems the company faces should be temporary. UnitedHealth Group has already largely moved past the cyberattack that occurred in February 2024. Although it cost the healthcare company over $2 billion, that issue has already proven to be a short-lived one. Higher Medicare Advantage costs are the main culprit behind UnitedHealth Group's suspension of its 2025 full-year guidance. But the company says that it expects to return to growth in 2026. I believe this prediction because it makes sense. Insurers sometimes incur higher-than-anticipated costs and feel the pain for a while. However, once they adjust premiums, the problem goes away. UnitedHealth Group announced the sudden departure of former CEO Andrew Witty at the same time it withdrew its 2025 outlook. Any worries investors might have had surrounding this move probably dissipated quickly after they learned Stephen Hemsley was returning to run the company. Hemsley served as CEO from 2006 through 2017, a period when UnitedHealth Group stock more than tripled. I also view the two biggest threats to UnitedHealth Group as iffy. What are those threats? An alleged U.S. Department of Justice criminal investigation of the company and President Trump's stated goal to eliminate pharmacy benefits managers (PBMs). Noted that I used the word "alleged" to describe the U.S. Department of Justice probe. The Wall Street Journal reported on May 14, 2025, that "people familiar with the matter" revealed that the DOJ had launched a criminal investigation of UnitedHealth Group for possible Medicare fraud. However, the company quickly responded that it hadn't been notified of any DOJ investigation. That status hasn't changed. President Trump did announce that he wants to "cut out the middleman," a clear reference to PBMs. That's easier said than done, though, to put it mildly. Removing PBMs from the U.S. healthcare system would require a detailed, comprehensive plan that so far has not been provided. That plan would also have to pass in both the Senate and the House of Representatives. You can bet that the PBM industry, including UnitedHealth Group, would lobby fiercely against any such legislation. I think this threat, while serious, has a relatively low probability of actually materializing. Finally, I think all these issues are fully baked into UnitedHealth Group's share price. The stock currently trades at a forward price-to-earnings ratio of around 13.3. That's well below the S&P 500 healthcare sector forward earnings multiple of 16.6. It's also the lowest valuation for UnitedHealth Group in more than a decade. Could the stock fall further? Maybe, but I believe that UnitedHealth Group's share price has bottomed out. You might have noticed that UnitedHealth Group's share price has traded in a relatively narrow range since the steep decline in April and May. This trading pattern seems to confirm my view. Any good news for UnitedHealth Group could provide a nice catalyst. I predict that the company will have some positive developments in the not-too-distant future, potentially including new full-year guidance that calms investors. If I'm right, buying UnitedHealth Group stock now could pay off handsomely. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 HSBC Holdings is an advertising partner of Motley Fool Money. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends HSBC Holdings and UnitedHealth Group. The Motley Fool has a disclosure policy. Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Weight-loss drugs were said to be a game changer. Turns out the benefit might be thinner than thought
Weight-loss drugs were said to be a game changer. Turns out the benefit might be thinner than thought

Yahoo

time40 minutes ago

  • Yahoo

Weight-loss drugs were said to be a game changer. Turns out the benefit might be thinner than thought

Common GLP-1 weight loss drugs - including Wegovy and Ozempic - may not work for everyone in a 'real-world' setting, Cleveland Clinic researchers said Tuesday. The reason is that patients may take lower dosages or discontinue their treatment, negatively impacting the ability to control blood sugar levels in those who are pre-diabetic. The findings may have implications for people considering using the drugs, that are taken by more than eight million Americans every year. They've offered an alternative to traditional and taxing weight loss methods, such as diets and fitness. 'Our study shows that patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trials,' Dr. Hamlet Gasoyan, a researcher with Cleveland Clinic, said in a statement. 'According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomized clinical trial settings.' Gasoyan was the lead author of the study published on Tuesday in the Obesity Journal. 'Semaglutide has been extensively examined in robust clinical development programs, large real-world-evidence studies and has cumulatively over 33 million patient years of exposure,' a Novo Nordisk spokesperson told The Independent. 'Semaglutide's efficacy and safety have been extensively demonstrated in people with obesity/overweight with robust evidence for improving health outcomes. Semaglutide has demonstrated improvements in cardiovascular death, stroke, and myocardial infarction.' A request for comment from Eli Lilly was not immediately returned to The Independent. The study focuses on drugs with the active ingredients semaglutide and tirzepatide; they include the U.S. Food and Drug-administration approved type 2 diabetes medications Zepbound and Mounjaro. The authors studied their effects on weight loss and blood sugar regulation in a real-world setting. They noted that previous randomized clinical trials have shown the efficacy of those medications. The authors monitored the health of nearly 7,900 adults who were severely obese. Of those, more than 1,300 had pre-diabetes at the study's start and were at a higher risk for developing type 2 diabetes: a chronic condition that affects a person's ability to use insulin and keep blood sugar at normal levels. Participants took the shots between 2021 and 2023. The researchers sorted patients who discontinued their obesity medications into two groups: those who did it within just three months and by three months to a year. The study's follow-up period ended last December. The most common reasoning for discontinuation of treatment in the real-world setting was due to the steep cost of the drugs and insurance, side effects and shortages. Notably, since the study's, prices have started to fall. Of the participants, more than 20 percent discontinued their medications early and 32 percent discontinued their medications late. Furthermore, the authors noted than more than 80 percent had been on the lower dosages needed to sustain a therapeutic effect. For semaglutide, that's equal to or less than 1 milligram and equal to or less than 7.5 milligrams for tirzepatide. Following a year of treatment, the average weight reduction was 3.6 percent among participants who discontinued their treatment early, compared to 6.8 percent for those who discontinued their treatment late. But, those who did not discontinue treatment and were on the highest dosages necessary lost the most weight, at up to 13.7 percent with semaglutide and 18 percent with tirzepatide. Participants had higher odds of achieving 10 percent or greater weight reduction after one year of treatment if they did not discontinue their medications or did so late, were on the highest dosages needed for a therapeutic effect, received tirzepatide, and were women. Tracking the maintenance of blood sugar levels in those with pre-diabetes, the researchers said just a third of those who discontinued their treatment early experienced normal blood sugar levels compared to 41 percent who discontinued their treatment late and 67.9 percent who did not discontinue treatment. Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight compared to those who did not, their weight trajectories remained relatively stable. They said that would be the subject of additional research. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' explained Gasoyan.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store